Practical Formulation Strategies For Poorly Soluble APIs

Modern drug candidates skew larger, more lipophilic, and markedly less water-soluble than earlier pharmaceutical generations, and poor physicochemical properties remain a leading driver of late-stage attrition. This paper examines how early solubility and solid-state screening shape viable formulation paths, from particle size reduction and salt formation to amorphous solid dispersions, lipid-based systems, and cyclodextrin complexation.

Drawing on development cases from Eurofins CDMO Alphora, it shows why dissolution anomalies, solid-state instability, and analytical limitations are rarely separable problems, and why formulation, analytical, and solid-state teams working in isolation tend to misdiagnose developability risk.

Examine the strategies and integrated screening approach that help determine, before pivotal studies begin, whether a poorly soluble API can achieve reliable exposure.